Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/31255301/ below:

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

Meta-Analysis

Collaborators, Affiliations

• HPV Vaccination Impact Study Group: Hammad Ali, Marie-Claude Boily, Vincenzo Baldo, Paul Brassard, Julia M L Brotherton, Denton Callander, Marta Checchi, Eric P F Chow, Silvia Cocchio, Tina Dalianis, Shelley L Deeks, Christian Dehlendorff, Basil Donovan, Christopher K Fairley, Elaine W Flagg, Julia W Gargano, Suzanne M Garland, Nathalie Grün, Bo T Hansen, Christopher Harrison, Eva Herweijer, Teresa M Imburgia, Anne M Johnson, Jessica A Kahn, Kimberley Kavanagh, Susanne K Kjaer, Erich V Kliewer, Bette Liu, Dorothy A Machalek, Lauri Markowitz, David Mesher, Christian Munk, Linda Niccolai, Mari Nygård, Gina Ogilvie, Jeannie Oliphant, Kevin G Pollock, Maria Jesús Purriños-Hermida, Megan A Smith, Marc Steben, Anna Söderlund-Strand, Pam Sonnenberg, Pär Sparen, Clare Tanton, Cosette M Wheeler, Petra J Woestenberg, Bo Nancy Yu

• ¹ Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada.
• ² Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada; Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, QC, Canada.
• ³ Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada; Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, QC, Canada; Department of Infectious Disease Epidemiology, Imperial College, London, UK. Electronic address: marc.brisson@crchudequebec.ulaval.ca.

• PMID: 31255301
• PMCID: PMC7316527
• DOI: 10.1016/S0140-6736(19)30298-3

Item in Clipboard

Meta-Analysis

Mélanie Drolet et al. Lancet. 2019.

• HPV Vaccination Impact Study Group: Hammad Ali, Marie-Claude Boily, Vincenzo Baldo, Paul Brassard, Julia M L Brotherton, Denton Callander, Marta Checchi, Eric P F Chow, Silvia Cocchio, Tina Dalianis, Shelley L Deeks, Christian Dehlendorff, Basil Donovan, Christopher K Fairley, Elaine W Flagg, Julia W Gargano, Suzanne M Garland, Nathalie Grün, Bo T Hansen, Christopher Harrison, Eva Herweijer, Teresa M Imburgia, Anne M Johnson, Jessica A Kahn, Kimberley Kavanagh, Susanne K Kjaer, Erich V Kliewer, Bette Liu, Dorothy A Machalek, Lauri Markowitz, David Mesher, Christian Munk, Linda Niccolai, Mari Nygård, Gina Ogilvie, Jeannie Oliphant, Kevin G Pollock, Maria Jesús Purriños-Hermida, Megan A Smith, Marc Steben, Anna Söderlund-Strand, Pam Sonnenberg, Pär Sparen, Clare Tanton, Cosette M Wheeler, Petra J Woestenberg, Bo Nancy Yu

• ¹ Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada.
• ² Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada; Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, QC, Canada.
• ³ Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada; Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, QC, Canada; Department of Infectious Disease Epidemiology, Imperial College, London, UK. Electronic address: marc.brisson@crchudequebec.ulaval.ca.

• PMID: 31255301
• PMCID: PMC7316527
• DOI: 10.1016/S0140-6736(19)30298-3

Item in Clipboard

Background: More than 10 years have elapsed since human papillomavirus (HPV) vaccination was implemented. We did a systematic review and meta-analysis of the population-level impact of vaccinating girls and women against human papillomavirus on HPV infections, anogenital wart diagnoses, and cervical intraepithelial neoplasia grade 2+ (CIN2+) to summarise the most recent evidence about the effectiveness of HPV vaccines in real-world settings and to quantify the impact of multiple age-cohort vaccination.

Methods: In this updated systematic review and meta-analysis, we used the same search strategy as in our previous paper. We searched MEDLINE and Embase for studies published between Feb 1, 2014, and Oct 11, 2018. Studies were eligible if they compared the frequency (prevalence or incidence) of at least one HPV-related endpoint (genital HPV infections, anogenital wart diagnoses, or histologically confirmed CIN2+) between pre-vaccination and post-vaccination periods among the general population and if they used the same population sources and recruitment methods before and after vaccination. Our primary assessment was the relative risk (RR) comparing the frequency (prevalence or incidence) of HPV-related endpoints between the pre-vaccination and post-vaccination periods. We stratified all analyses by sex, age, and years since introduction of HPV vaccination. We used random-effects models to estimate pooled relative risks.

Findings: We identified 1702 potentially eligible articles for this systematic review and meta-analysis, and included 65 articles in 14 high-income countries: 23 for HPV infection, 29 for anogenital warts, and 13 for CIN2+. After 5-8 years of vaccination, the prevalence of HPV 16 and 18 decreased significantly by 83% (RR 0·17, 95% CI 0·11-0·25) among girls aged 13-19 years, and decreased significantly by 66% (RR 0·34, 95% CI 0·23-0·49) among women aged 20-24 years. The prevalence of HPV 31, 33, and 45 decreased significantly by 54% (RR 0·46, 95% CI 0·33-0·66) among girls aged 13-19 years. Anogenital wart diagnoses decreased significantly by 67% (RR 0·33, 95% CI 0·24-0·46) among girls aged 15-19 years, decreased significantly by 54% (RR 0·46, 95% CI 0.36-0.60) among women aged 20-24 years, and decreased significantly by 31% (RR 0·69, 95% CI 0·53-0·89) among women aged 25-29 years. Among boys aged 15-19 years anogenital wart diagnoses decreased significantly by 48% (RR 0·52, 95% CI 0·37-0·75) and among men aged 20-24 years they decreased significantly by 32% (RR 0·68, 95% CI 0·47-0·98). After 5-9 years of vaccination, CIN2+ decreased significantly by 51% (RR 0·49, 95% CI 0·42-0·58) among screened girls aged 15-19 years and decreased significantly by 31% (RR 0·69, 95% CI 0·57-0·84) among women aged 20-24 years.

Interpretation: This updated systematic review and meta-analysis includes data from 60 million individuals and up to 8 years of post-vaccination follow-up. Our results show compelling evidence of the substantial impact of HPV vaccination programmes on HPV infections and CIN2+ among girls and women, and on anogenital warts diagnoses among girls, women, boys, and men. Additionally, programmes with multi-cohort vaccination and high vaccination coverage had a greater direct impact and herd effects.

Funding: WHO, Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé.

Copyright © 2019 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Declaration of interests

The authors listed in this paper declare no competing interests. Please see the appendix for the declaration of interests of the authors listed as study group members.

Two articles on…

Two articles on anogenital warts from our previous systematic review and…

Two articles on anogenital warts from our previous systematic review and meta-analysis were not included in this update: Sandø and colleagues and Nsouli-Maktabi and colleagues. Sandø and colleagues was one of two studies we had previously found that analysed the entire Danish population for the same period, but we included the study by Baandrup and colleagues in our current analysis because they updated their data and had a longer follow-up. We excluded the study by Nsouli-Maktabi and colleagues because it was done among members of the US armed forces and not in the general population. NHANES=National Health and Nutrition Examination Survey.

HPV=human…

HPV=human papillomavirus. *p values are associated with the χ² statistic.

*p values are associated with the χ² statistic.

We stratified by number of cohorts vaccinated and routine vaccination coverage. Countries with single-cohort vaccination and/or low coverage (in red) were Canada (Ontario, Manitoba^,) and Italy with single-cohort vaccination and high coverage; and Germany,^, Belgium, Sweden,^, and the USA^,, with multi-cohort vaccination and low coverage. Countries with multi-cohort vaccination and high coverage (in blue) were Australia,^,,,, Denmark,^, New Zealand,^, and Canada (Quebec).

CIN2+=cervical intraepithelial neoplasia grade 2+. *p values are associated with the χ² statistic.

Countries with multi-cohort vaccination and high coverage (≥50%) were Australia,^, Canada (British Columbia), Denmark, Scotland, and the USA.^,,, For CIN2+ analysis, the USA was categorised as a country with multi-cohort vaccination and high routine vaccination coverage because several US data indicate an association between screening participation and human papillomavirus vaccination.^,,, Thus, the vaccination coverage among screened girls and women is likely to be higher than the overall vaccination coverage in the population. We did a sensitivity analysis excluding the USA from countries with multi-cohort and high vaccination coverage and results were unchanged. CIN2+=cervical intraepithelial neoplasia grade 2+.

• Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

  Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M. Drolet M, et al. Lancet Infect Dis. 2015 May;15(5):565-80. doi: 10.1016/S1473-3099(14)71073-4. Epub 2015 Mar 3. Lancet Infect Dis. 2015. PMID: 25744474 Free PMC article. Review.

• The impact of Germany's human papillomavirus immunization program on HPV-related anogenital diseases: a retrospective analysis of claims data from statutory health insurances.

  Goodman E, Reuschenbach M, Viering T, Luzak A, Greiner W, Hampl M, Jacob C. Goodman E, et al. Arch Gynecol Obstet. 2024 Nov;310(5):2639-2646. doi: 10.1007/s00404-024-07692-y. Epub 2024 Sep 4. Arch Gynecol Obstet. 2024. PMID: 39230793 Free PMC article.

• Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

  Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Arbyn M, et al. Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3. Cochrane Database Syst Rev. 2018. PMID: 29740819 Free PMC article. Review.

• Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

  Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M. Van de Velde N, et al. J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395. Epub 2012 Oct 27. J Natl Cancer Inst. 2012. PMID: 23104323

• High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys.

  Rob F, Tachezy R, Pichlík T, Rob L, Kružicová Z, Hamšíková E, Šmahelová J, Hercogová J. Rob F, et al. Dermatol Ther. 2017 Jan;30(1). doi: 10.1111/dth.12435. Epub 2016 Oct 9. Dermatol Ther. 2017. PMID: 27723194

• Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women.

  Kjaer SK, Falkenthal TEH, Sundström K, Munk C, Sture T, Bautista O; Thomas Group; Rawat S, Luxembourg A. Kjaer SK, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2377903. doi: 10.1080/21645515.2024.2377903. Epub 2024 Oct 7. Hum Vaccin Immunother. 2024. PMID: 39373579 Free PMC article.

• Males' Access to Human Papillomavirus Vaccination in Resource-Limited Settings.

  Gezimu W, Bekele F, Bekana T, Demeke A. Gezimu W, et al. Immunotargets Ther. 2024 Feb 17;13:95-98. doi: 10.2147/ITT.S451659. eCollection 2024. Immunotargets Ther. 2024. PMID: 38390613 Free PMC article.

• Human papillomavirus vaccination uptake in low-and middle-income countries: a meta-analysis.

  Dorji T, Nopsopon T, Tamang ST, Pongpirul K. Dorji T, et al. EClinicalMedicine. 2021 Apr 17;34:100836. doi: 10.1016/j.eclinm.2021.100836. eCollection 2021 Apr. EClinicalMedicine. 2021. PMID: 33997733 Free PMC article.

• Genital and Oral HPV Geno-Prevalence Measured through Urine and Saliva Samples in Young Adults in Italy.

  Napolitano F, Angelillo S, Bianco A, Di Giuseppe G, Di Onofrio V, Licata F, Liguori G, Nobile CGA, Pavia M, Pelullo CP, Zito Marino F, Angelillo IF. Napolitano F, et al. Vaccines (Basel). 2024 Feb 16;12(2):205. doi: 10.3390/vaccines12020205. Vaccines (Basel). 2024. PMID: 38400188 Free PMC article.

• Human Papillomavirus Immunization in Rural Primary Care.

  Gunn R, Ferrara LK, Dickinson C, Stock I, Griffith-Weprin J, Wiser A, Hatch B, Fagnan LJ, Carney PA, Davis MM. Gunn R, et al. Am J Prev Med. 2020 Sep;59(3):377-385. doi: 10.1016/j.amepre.2020.03.018. Epub 2020 Jun 27. Am J Prev Med. 2020. PMID: 32605866 Free PMC article.

1. 1. Bruni L, Diaz M, Barrionuevo-Roses L, et al. Worldwide female and male HPV vaccination coverage from 2006 to 2016. International Papillomavirus Conference; Cape Town; Feb 28–March 4, 2017.
2. 1. Cervical Cancer Action. Global progress in HPV vaccination. http://www.cervicalcanceraction.org/comments/maps.php (accessed May 23, 2018).
3. 1. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15: 565–80. - PMC - PubMed
4. 1. Franco E, Schiffman M, Wacholder S, Stanley M. Methodological issues for trials of vaccine efficacy against HPV types 16 and 18 In: ARC HPV Working Group. Primary end-points for prophylactic vaccine trials. Lyon: International Agency for Research on Cancer, 2014: 39–45.
5. 1. WHO. Human papillomavirus vaccines: WHO position paper, May 2017–recommendations. Vaccine 2017; 35: 5753–55. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3